Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
0 hedge funds and large institutions have $0 invested in Clovis Oncology, Inc. in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $520K → $0 (-$520K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RMC
Resources Management Corp
West Hartford,
Connecticut
|
-$518K |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$2.18K |
CLVS Hedge Fund Activity: Q2 2023 in Review
0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q2 2023, worth a combined $0 — down 100% from $520K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CLVS and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Resources Management Corp, exiting entirely with an estimated $518K sold.
- 0 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q2 2023, down from 2 in Q1 2023.
- Funds reported $0 of Clovis Oncology, Inc. stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Clovis Oncology, Inc. positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest Clovis Oncology, Inc. seller in Q2 2023 was Resources Management Corp, an estimated $518K sold.
Based on aggregated 13F filings for Q2 2023.